Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is TB-500? Identity and Documentation for Laboratory Research

A research-use identity note on TB-500: how the name is used in catalogs and literature, why it should not be conflated with BPC-157, and which lot documents to file.

What Is TB-500? Identity and Documentation for Laboratory Research

TB-500 is a synthetic peptide name used in research catalogs and in a body of literature associated with a fragment of thymosin beta-4. For laboratory procurement, the useful first questions are identity and documentation: what was ordered, what the label and report actually name, and whether those records match.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only.

Name, identity, and related terms

Catalogs and papers do not always use a single naming convention. TB-500 may appear alongside references to thymosin beta-4, to a fragment, or to a research-code synonym. Those labels are not automatically the same specification. A brief should use the exact catalog name and, where available, the sequence or fragment description given on the quotation and the analytical report.

Do not collapse TB-500 into a neighboring catalog name. It is not BPC-157, and it is not a generic “tissue peptide.” If a source uses both names in one sentence, keep two rows in the file until the identities are confirmed. The comparison page BPC-157 vs TB-500: Different Sequences, Separate Lot Files is written for that purpose. The BPC-157 identity note is What Is BPC-157?.

Literature that discusses actin-related or cell-migration laboratory models is sometimes cited near this name. Those citations describe experimental systems. They are not procurement specifications, and they are not claims about use in people or animals. When a paper is added to the file, record whether the material in that paper was analytically identified, and do not treat the paper as a substitute for the lot report on the current offer.

Reading the literature without transferring it

As with other research peptides, study systems, endpoints, and reporting quality vary. Findings reported in one model should not be treated as interchangeable with another, and they should not be filed as a reason to skip identity or purity documents. BPC-157 in Preclinical Literature: Evidence Limits and Material Quality is a related discussion of evidence limits; the same discipline — do not over-read a paper, and do not substitute a paper for a lot file — applies here.

If a secondary article ranks or blends TB-500 with other catalog names, treat it as a pointer to primary sources, not as a completed review.

Identity checks for a TB-500 research-material file
Check What to confirm
Catalog name The exact SKU or product name on the quotation, not a family phrase.
Sequence or fragment wording Whether the report and the brief use the same identity language.
Lot and sample identifiers A match, or a stated relationship, between the report and the offered goods.
Neighboring names BPC-157 or combination presentations listed as separate rows, if present.

Documentation for the lot on offer

Request the report that belongs to the offered lot, or a clear statement that a file is a reference sample. Review product name, identifiers, methods, report date, and completeness. What Is a Peptide COA? defines the document; How to Read a Peptide COA is the review checklist; HPLC vs Mass Spectrometry for Peptide Lot Review and Third-Party Peptide Testing, Explained cover method and issuer questions; lot traceability covers the wider record chain.

Catalog specifications, where published, appear in the product directory. There is not a standalone public landing page for every catalog name, including TB-500; use the directory and the COA Library, then confirm the exact SKU, specification, and current-lot documents in the inquiry. For packing and documentation at supply scale, see wholesale peptides.

Trial quantities and a written brief

If you are assessing the material as a new catalog line, write a brief that can be filed: exact name, specification, vial and box counts, destination, and the documents you need to see. A trial order, where the catalog allows it, should use the same acceptance criteria as a later shipment. For many B2B catalogs, including Velnacor’s, a standard minimum is one box of ten vials; confirm the unit basis on the quotation.

Give neighboring names their own rows if they appear in the same request. Shared shipping or a single conversation does not merge two specifications. How to Evaluate a Peptide Supplier: B2B Checklist is the process page to keep those questions consistent. Order-specific questions can go through the inquiry list.

Keep arrival notes with the analytical file. A complete report does not replace a receiving check, and a complete receiving check does not replace identifiers on the report. Cold-Chain Records for Lyophilized Research Peptides covers that part of the record.

What this page does not claim

This is an identity and documentation note. It does not describe a protocol, a preferred model, or a biological outcome. A complete lot file supports laboratory accountability. It does not turn the material into anything other than a research-use supply item.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0